BioAlliance Pharma Names Francois Sarkozy as Vice-Chairman of its Supervisory Board; Healthcare Industry Professional Brings Further Operational and International Experience to Specialty Pharma Company.

PARIS -- BioAlliance Pharma (EURONEXT:BIO)(BOURSE:BIO), an emerging specialty pharmaceutical company focused on the development of innovative therapeutics targeting drug resistance in cancer, HIV, and severe and opportunistic infections, announced today that Francois Sarkozy, MD, DEA, MBA, has been elected to serve as Vice-Chairman and independent member of its Supervisory Board (Conseil de Surveillance). Dr. Sarkozy is currently a Managing Partner of AEC Partners, a Paris-based healthcare consultancy.

"Francois is a quality addition to our board and we welcome the strong operational and international experience in healthcare he brings to the company," said Jean-Claude Deschamps, Chairman of the Supervisory Board.

"We look forward to benefiting from Francois' extensive industry knowledge gained through his experience in a large global healthcare company and as a former practising physician in the Paris Public Hospital Authority," said Dominique Costantini, MD, Chairman of the BioAlliance Management Board and CEO. "He will also bring a fresh perspective as BioAlliance makes the transition to a company focused on product commercialisation."

Dr. Sarkozy, age 46, has served as a Managing Partner at AEC Partners since 2001, where his assignments have included international medical and marketing strategy, project and resource management, business development and negotiation analysis, commercialisation of new products and change management in mergers and reorganizations. Previously, during the period 1990-2000, he was Medical Director, France, for Aventis Pharma; Medical & Pharmaceutical Director, France, for Hoechst Marion Roussel, where he was also Vice President and Head of Global Portfolio & Project Management, the latter position including three years in the U.S.; earlier, he held various positions with Roussel-Uclaf, including International Development Director, International Clinical Development Head, and International Product Manager for Antibiotics. From 1983 to 1990, he was an Assistant in the Respiratory Physiology Department of the Paris Public Hospital Authority, where he also did his internship (Interne des Hopitaux de Paris) in pediatrics. He holds an MBA from INSEAD.

About BioAlliance Pharma

BioAlliance Pharma (Euronext Paris: BIO) is an emerging specialty pharmaceutical company focused on the development of innovative therapeutics targeting drug resistance in cancer, HIV, and severe and opportunistic infections. The Company is developing three broad product ranges based on the Lauriad(R) adhesive technology which allows an early and prolonged release of therapeutic agents at the site of the disease, the Transdrug(R) nanoparticle technology designed specifically for intracellular targeting, and a New Chemical Entities programme focused on development of new drugs in oncology and HIV.

The Company's most advanced product, the Loramyc(R) (miconazole Lauriad(R)) 50 mg Bioadhesive Buccal Tablet, has completed two Phase III clinical trials in Europe for treatment of oropharyngeal candidiasis (OPC) in cancer and HIV patients. In September 2005, BioAlliance filed a request for Marketing Autorisation (MAA) in Europe for this product. Under an IND allowed by the US Food and Drug Administration (FDA), a pivotal Phase III trial of Loramyc(R) is expected to initiate in the US in 2006 for the same indication. A second product, acyclovir Lauriad(R), for the treatment of oral herpes, has completed a Phase I clinical trial in Europe. A Phase I/II trial in primary liver cancer (hepatocellular carcinoma or HCC) utilizing the Company's doxorubicin Transdrug(R) nanoparticle delivery technology is ongoing in Europe, and has been granted orphan drug status by the EMEA and the FDA.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements please refer to the Risk Factors (Facteurs de Risque) section of the prospectus approved by the AMF (visa number 05-803) (section 3 of the Company's Document de base filed with the AMF under the number I.05-132 on 15 November 2005 and section 2 of the Note d'operation dated 22 November 2005), as available on the AMF website http://www.amf-france.org or BioAlliance Pharma S.A.'s website http://www.bioalliancepharma.com.